logo-loader

Small Caps Watch: Actinogen reports Alzheimer’s trial results, Lumos expands into Portugal

Published: 09:39 19 Nov 2026 AEDT

Actinogen Medical Ltd - Small Caps Watch: Actinogen reports Alzheimer’s trial results, Lumos expands into Portugal

Australia’s small-cap stocks remained under pressure on Wednesday, with the S&P/ASX Small Ordinaries Index (XSO) falling 46.60 points, or 1.48%, to close at 3,097.40.

The index has now shed 224.80 points, or 6.77%, over the past five trading sessions, reflecting continued weakness across the smaller end of the Australian sharemarket.

Despite the broader market decline, company-specific developments continue to give investors fresh material to assess, particularly across biotechnology, medical diagnostics and critical minerals.

Actinogen reports mixed Alzheimer’s trial results, identifies benefit in older patients

Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) has reported topline results from its pivotal XanaMIA clinical trial, identifying encouraging signs of treatment benefit in older Alzheimer’s disease patients despite missing its primary statistical endpoint.

The placebo-controlled trial assessed oral emestedastat, known as Xanamem, over 36 weeks in 247 patients with mild to moderate Alzheimer’s disease and elevated levels of the pTau181 blood biomarker.

Across the overall study population, Xanamem produced a numerical improvement over placebo in delaying disease progression, but the difference was not statistically significant.

However, older participants demonstrated a clinically meaningful and sustained 30% slowing of disease progression, potentially opening a new treatment opportunity for patients with more advanced Alzheimer's disease.

Actinogen has filed a new patent application covering Xanamem treatment in this older patient population, which remains underserved by existing and emerging therapies.

The company also reported a favourable safety profile, with Xanamem well tolerated throughout the 36-week treatment period.

Early results from the trial's open-label extension showed no average disease progression over 24 weeks among the first 29 participants receiving active treatment.

Actinogen will continue the extension study, with its next data milestone expected in the first quarter of 2027 when approximately 100 participants have completed at least 24 weeks of treatment.

The company holds $18.9 million in cash, carries no debt and expects its funding to support operations into 2028.

Lumos Diagnostics expands FebriDx distribution into Portugal

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has expanded its European commercial footprint through a new distribution agreement for its FebriDx rapid diagnostic test in Portugal.

The company has signed a non-exclusive agreement with Portuguese medical device distributor Magnamed LDA, which will market FebriDx across the country's primary care, urgent care and hospital sectors.

Established in 1996, Magnamed supplies medical equipment and consumables to more than 300 customers across Portugal's public and private healthcare systems.

The distributor represents several international healthcare brands and maintains a specialist sales team supported by local product servicing and technical expertise.

For Lumos, the agreement provides access to an established healthcare distribution network without requiring the company to build its own sales infrastructure in Portugal.

FebriDx is designed to help healthcare professionals distinguish between bacterial and viral infections at the point of care, supporting faster treatment decisions and potentially reducing unnecessary antibiotic prescriptions.

The Portuguese agreement adds another market to Lumos' international commercialisation strategy as it seeks to increase adoption of FebriDx across healthcare networks.

Sovereign Metals appoints experienced mining executive to lead Kasiya development

Sovereign Metals Ltd (ASX:SVM, OTCQX:SVMLF, AIM:SVML) has confirmed that Tim Carstens has commenced his appointment as executive chair, strengthening the company's leadership as it advances the Kasiya Critical Minerals Project in Malawi towards financing, construction and production.

Carstens brings more than 25 years of senior resources industry experience, including leadership roles across mineral sands, iron ore and gold operations in Australia and internationally.

He previously served as managing director of Base Resources from its establishment in 2008 until its acquisition by US critical minerals company Energy Fuels in October 2024.

During his tenure, Carstens led Base Resources through the financing, construction and operation of the Kwale Mineral Sands Mine in Kenya, establishing a track record in delivering large-scale African mining developments.

His experience in securing project finance, managing construction and overseeing mining operations is expected to support Sovereign as it moves Kasiya through its next development stages.

Kasiya is a major undeveloped source of natural rutile and graphite, two minerals with applications across industrial manufacturing, aerospace, defence and battery supply chains.

The appointment comes as Sovereign focuses on turning the project's substantial resource base into a commercially operating mine.

Carstens will oversee development planning, financing arrangements and preparations for construction, positioning Sovereign for the next phase of Kasiya's progression towards production.

XanaMIA results: What's next for Actinogen Medical?

Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged...

9 hours, 44 minutes ago